Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares rose 3.5% during trading on Tuesday . The stock traded as high as $11.71 and last traded at $11.43. Approximately 19,890 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 297,836 shares. The stock had previously closed at $11.04.
Analyst Upgrades and Downgrades
MAZE has been the subject of several research analyst reports. JPMorgan Chase & Co. assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price objective for the company. Leerink Partnrs raised Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Leerink Partners assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price target for the company. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Finally, Guggenheim assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They set a "buy" rating and a $19.00 price target for the company. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $25.67.
Check Out Our Latest Analysis on MAZE
Maze Therapeutics Trading Up 2.3 %
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Stories
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
